Faculty

Back to Index
Ann F Mohrbacher, MD
Associate Professor of Clinical Medicine
Medical Director, Autologous Bone Marrow Transplant
Medicine
NOR 3462 Health Sciences Campus Los Angeles
+1 323 865 3924

Overview

Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.

Awards

American Society of Clinical Oncology: Career Development Award, 1995

Harvard University : A.B. Magna Cum Laude, 1983

Harvard University: Scholarship, 1983

Harvard University: ORNG Application Instance for Person, 1983

American Society of Clinical Oncology: ORNG Application Instance for Person, 1995

Harvard University : ORNG Application Instance for Person, 1983

American Society of Clinical Oncology: full name, 1995

Harvard University : full name, 1983

Harvard University: full name, 1983

American Society of Clinical Oncology: person in primary position, 1995

Harvard University : person in primary position, 1983

Harvard University: person in primary position, 1983

Harvard University : Mohrbacher, Ann, 1983

Harvard University: Mohrbacher, Ann, 1983

American Society of Clinical Oncology: Mohrbacher, Ann, 1995

Harvard University: HR job title, 1983

Harvard University : HR job title, 1983

American Society of Clinical Oncology: HR job title, 1995

American Society of Clinical Oncology: ORNG Application URL, 1995

Harvard University : ORNG Application URL, 1983

Harvard University: ORNG Application URL, 1983

Harvard University: sort order, 1983

American Society of Clinical Oncology: sort order, 1995

Harvard University : sort order, 1983

Harvard University : Organization, 1983

American Society of Clinical Oncology: Organization, 1995

Harvard University: Organization, 1983

Harvard University : email address, 1983

Harvard University: email address, 1983

American Society of Clinical Oncology: email address, 1995

American Society of Clinical Oncology: start date, 1995

Harvard University: start date, 1983

Harvard University : start date, 1983

Harvard University: ClinicalTrials, 1983

American Society of Clinical Oncology: ClinicalTrials, 1995

Harvard University : ClinicalTrials, 1983

Harvard University: has ORNG Application Instance Data, 1983

American Society of Clinical Oncology: has ORNG Application Instance Data, 1995

American Society of Clinical Oncology: Associate Professor, 1995

Harvard University : Associate Professor, 1983

Harvard University: label, 1983

American Society of Clinical Oncology: label, 1995

Harvard University : label, 1983

American Society of Clinical Oncology: award conferred by, 1995

Harvard University: award conferred by, 1983

Harvard University : award conferred by, 1983

American Society of Clinical Oncology: Faculty Rank, 1995

Harvard University : Faculty Rank, 1983

Harvard University: Faculty Rank, 1983

Harvard University: is primary position, 1983

Harvard University : is primary position, 1983

American Society of Clinical Oncology: is primary position, 1995

Harvard University : ct_data, 1983

Harvard University: ct_data, 1983

American Society of Clinical Oncology: ct_data, 1995

Harvard University : http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^336-120, 1983

Harvard University: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^336-120, 1983

American Society of Clinical Oncology: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^336-120, 1995

Harvard University : has ORNG Application Instance Data, 1983

Harvard University: Associate Professor, 1983

Harvard University: ORNG Application Instance Data value, 1983

Harvard University : ORNG Application Instance Data value, 1983

American Society of Clinical Oncology: ORNG Application Instance Data value, 1995

Harvard University: Associate Professor of Clinical Medicine, 1983

Harvard University : Associate Professor of Clinical Medicine, 1983

American Society of Clinical Oncology: Associate Professor of Clinical Medicine, 1995

Harvard University: Keck School of Medicine of USC, 1983

American Society of Clinical Oncology: Keck School of Medicine of USC, 1995

Harvard University : Keck School of Medicine of USC, 1983

American Society of Clinical Oncology: Agent, 1995

Harvard University : Agent, 1983

Harvard University: Agent, 1983

American Society of Clinical Oncology: Position, 1995

Harvard University : Position, 1983

Harvard University: Position, 1983

American Society of Clinical Oncology: first name, 1995

Harvard University: first name, 1983

Harvard University : first name, 1983

Harvard University: has faculty rank, 1983

Harvard University : has faculty rank, 1983

American Society of Clinical Oncology: has faculty rank, 1995

Publications

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9; 127(23):2833-40. View in: PubMed

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016 Apr; 96(4):375-80. View in: PubMed

An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. Med Oncol. 2013 Dec; 30(4):744. View in: PubMed

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012 Jul 19; 120(3):552-9. View in: PubMed

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2012 Jun 1; 30(16):1960-5. View in: PubMed

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. View in: PubMed

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011 Jan; 67(1):57-67. View in: PubMed

A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. View in: PubMed

Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol. 2007 May; 60(5):562-4. View in: PubMed

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006 Feb 15; 106(4):848-58. View in: PubMed

B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther. 2005; 7 Suppl 3:S19-25. View in: PubMed

TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion. 2003 May; 43(5):641-5. View in: PubMed

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer. 2002 May 15; 94(10):2645-52. View in: PubMed

Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000 May 1; 95(9):2990-2. View in: PubMed

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999 Jun; 17(6):1851-7. View in: PubMed

The influence of patient-related factors on ex vivo retroviral-mediated gene transfer into mobilized peripheral blood myeloid progenitors. Hum Gene Ther. 1998 May 1; 9(7):1061-8. View in: PubMed

High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults. Hum Gene Ther. 1996 Mar 20; 7(5):669-84. View in: PubMed

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993 Dec 15; 82(12):3712-20. View in: PubMed

Regulation of c-jun gene expression in human T lymphocytes. Blood. 1993 Mar 15; 81(6):1540-8. View in: PubMed

Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res. 1992 Oct; 16(10):951-9. View in: PubMed

Powered bySC CTSI